Clinical Trials Sponsored by Accera, Inc

Total 35816 results

Acerta Pharma BV

Active, not recruiting

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

United States, United Kingdom
Acerta Pharma BV

Active, not recruiting

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Chronic Lymphocytic Leukemia

Austria, Italy, Spain, United Kingdom, Belgium, Taiwan, France, Korea, Republic of, Hungary, United States, Ukraine, Canada, Australia, Germany, Israel, Czechia, Russian Federation, Slovakia, Poland, Bulgaria, New Zealand, Sweden, C... and more
Acerta Pharma BV

Active, not recruiting

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL (ElevateTN)

Chronic Lymphocytic Leukemia

United States, Italy, Spain, Belgium, Brazil, Poland, United Kingdom, Canada, Germany, Australia, Israel, Hungary, France, New Zealand, Chile, Lithuania, Sweden, Colombia
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Waldenström Macroglobulinemia (WM)

Spain, United States, United Kingdom, France, Italy, Greece, Netherlands
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

Hepatic Insufficiency

United States
Acerta Pharma BV

Terminated

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
TeneoFour Inc.
Novotech (Australia) Pty Limited

Completed

A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers

Healthy Volunteer

Australia
Akcea Therapeutics

Recruiting

TEGSEDI Pregnancy Surveillance Program

Pregnancy | Hereditary Transthyretin-mediated Amyloidosis With Polyneropathy

United States
Akcea Therapeutics

Completed

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin

Cardiovascular Diseases | Elevated Lipoprotein(a)

Canada
Akcea Therapeutics

Completed

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel

Cardiovascular Diseases | Elevated Lipoprotein(a)

Canada
Ocera Therapeutics

Completed

Safety and Efficacy of AST-120 in the Treatment of Pouchitis

Pouchitis

United States
Avera Pharmaceuticals

Completed

The Efficacy and Safety of Gantacurium Chloride for Injection in Tracheal Intubation in Healthy Adult Patients Undergoing Surgery Under General Anesthesia

Healthy

Germany
Ocera Therapeutics

Terminated

Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI

Gastroesophageal Reflux Disease (GERD)

United States
Ocera Therapeutics

Terminated

Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis

Pouchitis

United States
Avera Pharmaceuticals

Terminated

Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity

Overactive Bladder Syndrome

Netherlands, United Kingdom
Accurx
Lindus Health

Completed

A Research Study to Explore the Impact of GP Support Via Text Messages to Patients With Asthma and/or COPD

Asthma | COPD

United Kingdom
Acerta Pharma BV

Active, not recruiting

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, Italy, Spain, United Kingdom, Belgium, Denmark, Hungary, Poland, Australia, Germany, Israel, Netherlands, Turkey, France, New Zealand
Acerta Pharma BV

Active, not recruiting

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United Kingdom, Poland
Acerta Pharma BV

Completed

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

Healthy Participants

United States
Acerta Pharma BV

Terminated

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

DLBCL | Richter Syndrome

United Kingdom, United States
Acerta Pharma BV

Completed

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

Rheumatoid Arthritis

United States
Athera Biotechnologies AB

Terminated

Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a

Cardiovascular Diseases | Arterial Inflammation

Sweden, Netherlands
Access Business Group

Completed

A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism

Hyperlipidemia

United States
Access Business Group

Completed

ABG Oxidative Stress Study Protocol-1

Healthy

United States
Access Business Group

Completed

Effects of Plant Concentrate Blend on Oxidative Stress in Healthy Humans

Healthy

United States
Ash Access Technology

Unknown

A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis

End Stage Renal Disease

United States
Maria del Carmen Gogeascoechea Trejo
Adhera Health, Inc.

Not yet recruiting

Randomized Clinical Trial to Evaluate the Efficacy of a Digital Intervention for Patients With Type 2 Diabetes (DIAVERA)

Diabetes Mellitus Type 2

Mexico
Akcea Therapeutics

Recruiting

A Clinical Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Patients With hATTR-PN

Hereditary Transthyretin Amyloidosis With Polyneuropthy

United States, Canada
Ocera Therapeutics

Completed

AST-120 Used to Treat Mild Hepatic Encephalopathy (ASTUTE)

Mild Hepatic Encephalopathy

United States
Ocera Therapeutics

Completed

Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States, Belgium
Ocera Therapeutics

Completed

Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas

Intestinal Fistula | Inflammatory Bowel Disease

United States, Israel, Canada, United Kingdom, Germany, Belgium, Hungary, France, Austria, Czech Republic, Netherlands, Poland
Ocera Therapeutics

Completed

Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy (AST015)

Hepatic Encephalopathy

United States
Avera Pharmaceuticals

Completed

Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder

Social Phobia

United States
Universidad Autónoma de Encarnación
University of Valencia; Adhera Health, Inc.

Completed

MejoraCare-Paraguay: mHealth Solution for Chronic Patients During the COVID-19 Outbreak in Paraguay (MejoraCare_P)

Quality of Life | Stress | Emotional Adjustment

Paraguay
AZTherapies, Inc.
APCER Life Sciences; PharmaConsulting Group; KCAS Bio

Completed

Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease (COGNITE)

Alzheimer's Disease

United States, Australia, Poland, Czechia, Hungary, Bulgaria, Canada
Adhera Health, Inc.
Novo Nordisk A/S; Hospital Miguel Servet

Completed

Digital Health Intervention for Caregivers Emotional and Self-management Support of Children With Type 1 Diabetes (CARING-T1D)

Diabetes Mellitus, Type 1

Spain
Till Bärnighausen
Clinton Health Access Initiative Inc.

Completed

Early Access to ART for All in Swaziland: Effects on Economic Outcomes

HIV/AIDS
Clinton Health Access Initiative Inc.
UNICEF; Ministry of Health, Malawi

Completed

Point of Care Early Infant Diagnosis Patient Impact Study

HIV

Malawi
Acerta Pharma BV
AstraZeneca

Completed

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (PRISM)

Diffuse Large B Cell Lymphoma | NHL | Non-hodgkin's Lymphoma | DLBCL

United States, United Kingdom
AstraZeneca
Acerta Pharma, LLC

Completed

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

Bioavailability | B-cell Lymphoid Cancer

United States
AstraZeneca
Acerta Pharma BV

Completed

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

Infectious Disease

United States
Home Access Health Corporation

Completed

Comparison Study of Lay Person Finger Stick Versus Blood Draw

Diabetes

United States
Avera McKennan Hospital & University Health Center
Cellworks Group Inc.

Recruiting

A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients

Pan-cancer

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY)

Chronic Lymphocytic Leukemia

United States, Spain, Canada, Italy, Taiwan, Russian Federation, Turkey, Germany, Korea, Republic of, Brazil, Hungary, Poland, China, Sweden, Bulgaria, Israel, United Kingdom, Australia, Saudi Arabia, Austria, France, Czechia, South... and more

3

Subscribe